← PortfolioGov Pulse

Official federal signal for consultants

HHS · Notice · Rel 100 (Federal Register (major agencies))

Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS

Other · Health / life sciences · general, public-health, nih-funding

Source summary

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.

Analyst note

HHS published an official item relevant to other. Use the source link to verify scope before advising clients.

Public reaction (Reddit)

Insufficient public reaction to score sentiment.